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A considerable body of evidence supports a role for oxidative stress in breast carcinogenesis. Due to their role in producing energy
via oxidative phosphorylation, the mitochondria are a major source of production of reactive oxygen species, which may damage
DNA. The mitochondrial genome may be particularly susceptible to oxidative damage leading to mitochondrial dysfunction.
Genetic variants in mtDNA and nuclear DNA may also contribute to mitochondrial dysfunction. In this review, we address the
role of alterations in mtDNA in the etiology of breast cancer. Several studies have shown a relatively high frequency of mtDNA
mutations in breast tumor tissue in comparison with mutations in normal breast tissue. To date, several studies have examined
the association of genetic variants in mtDNA and breast cancer risk. The G10398A mtDNA polymorphism has received the most
attention and has been shown to be associated with increased risk in some studies. Other variants have generally been examined in
onlyoneortwostudies.Genome-wideassociationstudiesmayhelpidentifynewmtDNAvariantswhichmodifybreastcancerrisk.
In addition to assessing the main eﬀects of speciﬁc variants, gene-gene and gene-environment interactions are likely to explain a
greater proportion of the variability in breast cancer risk.
1.Introduction
Breast cancer has a complex, multifactorial etiology, with
contributions from both genetic and environmental factors.
Although its etiology is incompletely understood, it has
been estimated from studies of twins that hereditary factors
explain about 27% of the variation in breast cancer risk,
with the remainder being due to nonshared environmental
and lifestyle factors [1]. Factors that have been associated
with increased risk include increasing age, a history of breast
cancer in a ﬁrst-degree relative [2, 3], a history of benign
breast disease [4, 5], menstrual and reproductive factors [6–
8], use of hormone therapy [9, 10], a relatively high body
mass index (BMI) (in postmenopausal women) [11], alcohol
consumption [12], and possibly cigarette consumption [13],
while physical activity has been associated with reduced
breast cancer risk [14]. Dietary factors (e.g., a relatively high
fat intake and relatively low fruit and vegetable intake) have
also been postulated to play a role in the etiology of breast
cancer [15–17], although the epidemiologic evidence for this
is not consistent. Collectively, the generally accepted risk
factorsforbreastcancerexplainperhaps40%ofthevariation
in breast cancer incidence [18].
T h e r ei sn o wac o n s i d e r a b l eb o d yo fe v i d e n c et os u p p o r t
a role for oxidative stress in carcinogenesis [19]. Oxidative
stress is a disturbance in the balance between the production
of reactive species (RS) (including reactive oxygen species
(ROS))andantioxidantdefenses,resultinginarelativeexcess
of RS [19–21]. RS are unstable and can react with and
damage nuclear and mitochondrial DNA [22]. Additionally,
they may alter the expression of genes that stimulate cell
proliferationanddiﬀerentiation[22,23],andcauselipidper-
oxidation, protein modiﬁcation, and membrane disruption
[18].2 Journal of Oncology
Due to their role in producing energy via oxidative
phosphorylation, the mitochondria are a major source
of production of reactive oxygen species (ROS) [24, 25].
Furthermore, mitochondrial DNA (mtDNA) may be par-
ticularly vulnerable to oxidative damage because they lack
protective histones and the eﬃcient DNA repair mechanisms
present in the nucleus [24, 26, 27]. Indeed, the mutation
rate of mtDNA has been reported to be 10–200 times that
of nuclear DNA [28–30]. Damage to mtDNA due to ROS
may provide (at least in part) a mechanistic explanation for
the association with breast cancer of many of the risk factors
described above [18]. For example, risk of breast cancer
related to reproductive and hormonal factors could be due
to the metabolism of estradiol to reactive hydroxy radicals
through redox cycling of the catechol estrogens [18, 31],
while alcohol metabolism might also result in the generation
of ROS [32].
A possible role of the mitochondria in cancer was ﬁrst
postulated by Warburg 70 years ago [33], and most research
has focused on somatic mutations in mtDNA [34, 35].
Recently, however, a number of studies have addressed the
possibility that mitochondrial DNA variants may also play
a role in the etiology of speciﬁc cancers [24, 35, 36]. In
this review, we summarize what is known about the role
of oxidative stress in relation to cancer generally and to
breast cancer in particular, how exogenous and endogenous
exposures might contribute to oxidative stress, the function
of the mitochondrion and the mitochondrial genome, and
the possible role of mtDNA mutations and polymorphisms
inbreastcarcinogenesis.Finally,we discussspeciﬁctopics for
future research.
2. The Mitochondrion
Mitochondria are the energy-transducing organelles of
eukaryotic cells in which fuels that drive cellular metabolism
(e.g., carbohydrates and fats) are converted into adenosine
triphosphate (ATP) through the electron transport chain
and the oxidative phosphorylation system (the “respira-
tory chain”) [37, 38]. They are also involved in calcium
buﬀering and the regulation of apoptosis [39]. They arose
as intracellular symbionts in the evolutionary past, and
can be traced to the prokaryote α-proteobacterium [40].
There are hundreds to thousands of mitochondria per cell
[37].
Structurally, mitochondria have four compartments: the
outer membrane, the inner membrane, the intermembrane
space, and the matrix (the region inside the inner mem-
brane) (Figure 1)[ 37, 41]. The respiratory chain is located in
the inner mitochondrial membrane. It consists of ﬁve multi-
mericproteincomplexes:reducednicotinamideadeninedin-
ucleotide (NADH) dehydrogenase-ubiquinone oxidoreduc-
tase (complex I), succinate dehydrogenase-ubiquinone oxi-
doreductase (complex II), ubiquinone-cytochrome c oxido-
reductase(complexIII),cytochromec oxidase (complexIV),
and ATP synthase (complex V). In addition, the respiratory
chain requires 2 small electron carriers, ubiquinone and
cytochrome c.
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Figure 1: Mitochondrial structure adapted by Freitas [41]( R e p r o -
duced with permission from Freitas Nanomedicine, Volume I: Basic
Capabilities. Austin: Landes Bioscience, 1999:264), Vander et al.
(Reproduced with permission of The McGraw-Hill Companies)
[42], and Becker, Deamer (Used by permission of Pearson Educa-
tion, Inc.) [43].
Energy generation via ATP synthesis involves two coor-
dinated processes [37]: electrons (hydrogen ions derived
from NADH and reduced ﬂavin adenine dinucleotide) are
transportedalongthecomplexestomolecularoxygen,result-
ing in the production of water; simultaneously, protons are
pumped across the mitochondrial inner membrane (from
the matrix to the intermembrane space) by complexes I,
III, and IV. ATP is generated by the inﬂux of these protons
backintothemitochondrialmatrixthroughcomplexV(ATP
synthase).
3. OxidativeStress
Oxidative stress arises when there is an imbalance between
the production of reactive species (RS) and antioxidant
defenses in favor of the former, resulting in an increase in
cellular levels of RS [19, 22]. RS are molecular entities that
include reactive oxygen species (ROS), such as superoxide
anion, hydrogen peroxide, and the hydroxyl radical, reactive
nitrogen species (RNS), including the radicals nitric oxide
and nitrogen oxide, as well as reactive halogen and sulfur
species. They possess one or more unpaired electrons,
thereby rendering them inherently unstable [19, 20, 44].
ROS, the most extensively studied of the reactive species,
are highly reactive molecules or molecular fragments that
are continually produced in all aerobic organisms, mostly
as a consequence of aerobic respiration and oxidativeJournal of Oncology 3
phosphorylation [45]. The close proximity of mtDNA to the
siteofROSproductionmakesitmoresusceptibletooxidative
damage and may explain the high frequency of mtDNA
m u t a t i o n ss e e ni nc a n c e r[ 46].
R O Sh a v ep h y s i o l o g i c a lr o l e si nan u m b e ro fc e l l u l a r
processes, including eﬀects on vascular tone and platelet
adhesion, and, importantly, on intracellular and intercellular
signaling [45]( e . g . ,H 2O2 is a key intracellular messenger
at subtoxic levels in signaling pathways involving epidermal
growth factor and PI 3-kinases [47, 48]) and induction of
apoptosis and senescence [49, 50]. As mentioned earlier, the
mitochondriaareamajorsourceofROSproduction[24,25].
Speciﬁcally, during mitochondrial oxidative metabolism and
ATP synthesis, the majority of the oxygen consumed is
reduced to water. However, about 1%–5% of molecular oxy-
gen is converted to ROS, primarily superoxide anion, which
is formed by an initial one-electron reduction of molecular
oxygen[22,45].Superoxidecanbedismutatedbysuperoxide
dismutase to yield hydrogen peroxide. In the presence of
partially reduced metal ions, hydrogen peroxide is converted
through Fenton and Haber-Weiss reactions to a hydroxyl
radical, which is highly reactive and can interact with
nucleic acids, lipids, and proteins [44]. Other endogenous
sources of ROS production include neutrophils, eosinophils,
macrophages, and peroxisomes. ROS can be produced not
only as a result of endogenous cellular processes, but also in
response to exogenous exposures. Exogenous sources of ROS
productionincludechlorinatedcompounds,radiation,metal
ions, some peroxisome proliferating compounds, hormone
therapy, cigarette smoke, and ethanol [22, 51].
Antioxidant defenses operate through cellular, mem-
brane, and extracellular mechanisms [44]. Cellular mech-
anisms include the dismutase, peroxidase, and catalase
enzymes; additionally, intracellular ROS production is
decreased by the ability of mitochondrial cytochrome oxi-
dase to function catalytically in the electron transport chain
without releasing ROS [52]. Cell membrane defenses include
antioxidants suchasvitamin E, beta-carotene,and coenzyme
Q; furthermore, membrane structure is important, in that
resistance to antioxidant attack is enhanced by having
appropriate proportions of cholesterol and phospholipids.
Extracellular antioxidant defenses include the metal-binding
proteins (e.g., transferrin), low molecular weight molecules
such as bilirubin and vitamin C, and extracellular forms of
glutathione peroxidases and superoxide dismutases [44].
4. OxidativeStress and Cancer
There is now substantial evidence to suggest that relative
increases in reactive species in the cell, either as a result of
physiological modiﬁcation or through exogenous exposures,
contribute to carcinogenesis [19, 22, 45]. There are a number
of possible mechanisms through which this might occur.
As mentioned earlier, RS can directly damage DNA. For
example, the hydroxyl radical may activate oncogenes or
inactivate tumor suppressor genes through point mutations,
activate chemical carcinogens, and prevent DNA repair [45].
RS might also stimulate the expansion of initiated cell
clones through modulation of genes related to apoptosis or
proliferation, with resultant stimulation of cell proliferation
and suppression of apoptosis [19, 45]. In addition, the eﬀects
ofRSmaybeinﬂuencedbypolymorphismsingenesinvolved
in carcinogen metabolism, antioxidant defenses, and DNA
repair [35].
5. OxidativeStress andBreast Cancer
Several lines of evidence provide support for a role of
oxidative stress in the etiology of breast cancer [18]. Markers
of oxidative damage, such as DNA adducts and lipid
peroxidation products (e.g., DNA-malondialdehyde (MDA)
adducts, 8-oxo-7,8-dihydro-2 -deoxyguanosine (8-oxodG)),
can be detected in breast tissue, and several relatively small
clinicalstudieshavemostlyshownthatlevelsofsuchmarkers
are higher in breast cancer tissue [53–57] and in adjacent
normal tissue from breast cancer cases [55, 58, 59] than
in breast tissue from those without breast cancer, although
two studies have shown the reverse [60, 61]. In cross-
sectional studies, higher levels of oxidative damage markers
have also been observed in the serum/plasma [62–69]a n d
urine [70] of breast cancer cases than those of controls,
albeit not consistently [71, 72]. In the only cohort study to
date, urinary 15-F2t-IsoP and 15-F2t-IsoPM levels (markers
of oxidative stress) were associated with increased risk of
postmenopausal breast cancer in women with relatively high
BMIs (≥25kg/m2)[ 73]. Also, urinary MDA excretion has
been observed to be higher in women with relatively high
breast density (indicative of increased breast cancer risk
[74]) than in those with less dense breast tissue [75]. In
contrast, in one study, MDA levels in nipple aspirate ﬂuid
were shown not to diﬀer between breast cancer cases and
controls, whereas levels of 8-iso-PGF2α,a n o t h e rm a r k e ro f
oxidative stress, were shown to be lower in cases than in
controls [76].
6.The MitochondrialGenome
Mitochondria contain their own genome, mitochondrial
DNA (mtDNA), which is transmitted through the female
germline [77]. MtDNA is located in the mitochondrial
matrix and is present in multiple copies per mitochondrion
[38, 77]. The human mitochondrial genome is a closed,
double-strandedDNAmoleculeof16,569bp,whichcontains
37 genes. Most of the genes are located on the heavy
(H) strand, which encodes for two ribosomal RNAs, 14
transfer RNAs (tRNAs), and 12 polypeptides (Figure 2)
[38]. The light (L) strand encodes for eight tRNAs and a
single polypeptide. The 13 protein products are subunits
of the enzyme complexes of the respiratory chain/oxidative
phosphorylation system [37]. Mammalian mtDNA does not
have introns, and has only a few intergenic sequences.
The displacement-loop (D-loop) region is a short, three-
stranded structure in which a short nucleic acid strand,
complementary to the L-strand, displaces the H-strand. The
D-loop is the major control site for mtDNA expression,4 Journal of Oncology
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Figure 2: See work by Taanman in [38]. The light (L) strand
encodes for eight tRNAs and a single polypeptide. The 13 protein
products are subunits of the enzyme complexes of the respiratory
chain/oxidative phosphorylation system (DiMauro and Schon,
2003) [37]. Mammalian mtDNA does not have introns, and has
only a few intergenic sequences. The displacement loop (D-loop)
region is a short, three-stranded structure in which a short nucleic
acid strand, complementary to the L-strand, displaces the H-
strand. The D-loop is the major control site for mtDNA expression,
containing the leading-strand origin of replication and the major
promoters for transcription [38].
containing the leading-strand origin of replication and the
major promoters for transcription [38].
7.The Mitochondrial Genome andCancer
The mitochondria are not only a major source of ROS pro-
duction, but, as mentioned earlier, they are also particularly
susceptible to damage by ROS because the mitochondrial
genome is close to the site of ROS production, lacks histones
and introns, and has much less eﬃcient DNA repair mech-
anisms than nuclear DNA [24, 26, 27, 46]. Given the roles
of the mitochondria in energy metabolism, generation of
reactiveoxygenspecies,aging,andtheinitiationofapoptosis,
mitochondrial damage could contribute to carcinogenesis by
causing dysfunctional mitochondrial-induced apoptosis and
driving cellular proliferation [78–80].
During cell division, mitochondria segregate randomly
among daughter cells [77]. In normal tissues, all copies
of mtDNA are identical (homoplasmy). When pathogenic
mutations of mtDNA arise, they usually aﬀect some but
not all mtDNAs within a cell. Hence, the aﬀected cells (and
associated tissues) will contain an admixture of mutant and
wild-type mtDNAs, a situation referred to as heteroplasmy.
In cancer cells, however, due to clonal expansion most
somatic mtDNA mutations appear to be homoplasmic [81].
8. AlterationsintheMitochondrialGenomeand
Breast Cancer
Experimentally, depletion of mtDNA-encoded oxidative
phosphorylation genes has been shown to result in tumori-
genic transformation of breast epithelial cells [82]. In
humans, several studies have shown a relatively high fre-
quency of mtDNA mutations in breast tumor tissue (range
20%–93%) [83–88], although the higher estimates may be
due partly to sample contamination [87]. Furthermore,
a recent study suggested that mtDNA D-loop MnlII site
mutations might be associated with increased breast cancer
risk [89], and two studies have demonstrated breast cancer-
speciﬁc deletions in mtDNA [88, 90].
In addition to somatic changes, mtDNA variants (poly-
morphisms) may have subtle eﬀects on ROS production,
and it has been postulated that if the variant reduces the
eﬃciency of mitochondrial functioning, the accumulation
of ROS may aﬀect cancer risk [91]. Hence, several studies
have examined the association between mtDNA variants
and breast cancer risk [24, 36, 91–98]( Table 1), but their
results do not allow clear conclusions to be drawn regarding
speciﬁc associations. The G10398A mtDNA polymorphism
has received the most attention, and breast cancer risk in
association with the 10398A allele has been shown to be
associated with increased risk in African-Americans [24],
Caucasians [91], and East Indians [94] in some studies; not
associated with altered risk in either African-Americans [97]
or in Caucasians [95, 96] in other studies; and associated
with decreased risk in one Caucasian (Polish) population
(reported as risk in association with A10398G) [93]. The
remaining investigations have shown no association with
the mtDNA D-loop (CA)n repeat polymorphism in Chinese
[98] or with a range of variants in a Spanish population
[95]. Bai et al. [91] examined risk in association with
69 mtDNA variants and observed a few that were asso-
ciated with altered risk. Most studies to date have been
relatively small [91, 93–95] and none has undertaken a
genome-wide approach, although the study of Bai et al.
[91] did focus on variants in the rRNA, mRNA, tRNA,
and D-loop regions of mtDNA. Only one study [24]
has involved a two-stage approach of ﬁrst identifying a
possible association and then testing it in an independent
sample.
It is conceivable that mtDNA variants might act jointly
to inﬂuence breast cancer risk. Furthermore, several factors
involved or potentially involved in the etiology of breast
cancer—estrogens, cigarette smoking, alcohol consumption,
and caloric intake—might modify mitochondrial function.
Investigation of interactions of variants with each other and
with environmental exposures is warranted because once
patterns of association and interaction are understood, the
eﬀects of speciﬁc genes and environmental exposures on
phenotype may be estimated more accurately [99]. In this
regard, two studies have investigated interactions between
mtDNA variants and breast cancer risk [36, 92]. In a
relatively large study Canter et al. [92] reported a signiﬁcant
interaction between G10398A and T4216C in relation to
breast cancer risk in African-American women. In a smallerJournal of Oncology 5
Table 1: Association studies of mtDNA variants and breast cancer risk.
Reference Study subjects∗ Source of study subjects MtDNA variant (s) OR (95% CI)
∗∗
Canter et al.
[24]
48 AA cases, 54 AA controls (USA) Hospital-based G10398A 2.90 (0.61–18.3)
654 AA cases, 605 AA controls
(USA) Population-based G10398A 1.60 (1.10–2.31)
879 White cases, 760 White controls
(USA) 1.03 (0.81–1.31)
Canter et al.
[92]
AA subjects as in Canter et al.
(2005) T4216C
∗G10398A 3.31(1.07–10.25)
Darvishi et al.
[94]
124 cases, 273 ethnically matched
controls (India) Details not provided G10398A 1.73 (1.13–2.66)
Bai et al. [91] 156 non-Jewish
European-American cases, 260
non-Jewish European-American
controls (USA)
Cases referred to
Molecular Genetics
Laboratory for BRCA1/2
testing; controls were
individuals referred for
genetic testing
69 variants tested.
Signiﬁcant results:
G9055A 3.03 (1.63–5.63)
A10398G 1.79 (1.14–2.81)
T16519C 1.98 (1.25–3.12)
T3197C 0.31 (0.13–0.75)
G13708A 0.47 (0.24–0.92)
Haplotype K 3.30 (1.63–5.63)
Haplotype U 0.37 (0.19–0.73)
Mosquera-
Miguel et al.
[95]
464 cases, 453 ethnicity-matched
controls (continental Spain), 302
cases, 295 ethnicity-matched
controls (Canary Islands)
Details not provided 25 variants tested None of the variants
was associated with
altered risk in either
study after
adjustment for
multiple testing
Covarrubias
et al. [36]
Same subjects as in Bai et al. [91] 17 variants tested for all
possible 2-way
interactions
A10398G
∗A12308G
(P = .004)
All other interactions
NS after control for
FWER
Setiawan et al.
[97]
542 AA cases, 282 AA controls
(USA) Population-based G10398A 1.73 (0.87–3.47)
391 AA cases, 460 AA controls
(USA) Multiethnic cohort G10398A 1.08 (0.62–1.86)
524 AA cases, 236 AA controls
(USA) Population-based G10398A 0.81 (0.43–1.51)
Ye et al. [98] 1058 Chinese cases, 1129 Chinese
controls (China)
Population-based D-loop (CA)n repeat
polymorphism:
(CA)5 1.00 (reference)
(CA)4 1.02 (0.85–1.21)
(CA)6 0.84 (0.50–1.41)
(CA)7 0.50 (0.27–0.93)
(CA)8–11 1.59 (0.64–3.91)
Czarnecka et al.
[93]
44 Polish cases, 100 Polish controls
(Poland)
Clinic-based cases,
population-based
controls
A10398G 9.51(2.64–33.88)
Pezzotti et al.
[96]
1561 cases, 2209 controls in Nurses’
Health Study; 678 cases, 669
controls in Women’s Health Study
Population-based A10398G
Nurses’ Health Study 1.01 (0.85–1.19)
Women’s Health Study 0.94 (0.72–1.22)
∗AA = African-American; NS = not signiﬁcant; FWER = familywise error rate
∗∗Canter et al. [24] estimates are crude estimates—adjustment for other factors in population-based component did not change them; Darvishi et al. [94]
estimates are crude; Bai et al. [91] P-values adjusted for familywise error rate.6 Journal of Oncology
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Figure 3: Schema showing how ROS may aﬀect mitochondrial and nuclear DNA leading to breast carcinogenesis.
study, Covarrubias et al. [36] evaluated associations between
breast cancer risk and two-way interactions between 17
mtDNA variants. One interaction, between variants 12308G
and 10398G, was highly statistically signiﬁcant, suggesting
that these variants increase a woman’s risk of breast cancer
by a factor of 3.
In relation to exogenous exposures, susceptibility to the
eﬀects of mitochondrial dysfunction may be particularly
important in estrogen-related cancers such as breast cancer,
because the normal metabolism of estradiol through redox-
cycling intermediates may also generate local ROS and
oxidative injury in the breast, thereby predisposing to
neoplastic transformation [24]. Furthermore, mitochondrial
transcription is enhanced by estrogen treatment, suggesting
that estrogen-induced mitochondrial transcription is likely
to contribute to breast carcinogenesis [51, 100]. Smoking-
related damage to respiratory chain function in lymphocytes
has been correlated with measures of oxidative damage [101,
102], and smoking-related oxidative damage has been shown
to inhibit mitochondrial enzyme activity in platelets and to
cause mitochondrial dysfunction in alveolar macrophages
[103]. Two recent studies have shown that cigarette smok-
ing is associated with an increase in mitochondrial DNA
copy number [101, 104], which might represent a com-
pensatory response to smoking-induced oxidative damage
[104]. Shen et al. [105] found that mtDNA copy number
had a signiﬁcant positive association with risk of breast
cancer and a signiﬁcant inverse association with several
importantendogenousantioxidants(glutathione,CuZnSOD
activity, and catalase) and the prooxidant myeloperoxidase,
suggesting that mtDNA copy number may be associated
with breast cancer risk, possibly through an oxidative stress
mechanism.
Alcohol consumption is associated with the generation
of ROS [18], and a recent study showed that alcohol
consumption was associated with an increase in breast
cancer risk only in those with the G allele of the A10398G
polymorphism [96]. Another recent study [106] found no
diﬀerence in the frequency of mtDNA mutations by alcohol
intake, dietary intake, or MnSOD genotype [106].
Finally, the mitochondria use oxidative phosphorylation
to convert dietary calories into usable energy, and they
generate ROS as a toxic by-product. Hence, it has been
proposed that interaction between dietary caloric intake at
modern levels (in conjunction with a sedentary lifestyle) and
mtDNA polymorphisms favorable for selective adaptation
to cold Northern climates during human evolution might
inﬂuence disease risk [79]. In this regard, it is of interest
that insulin-resistant individuals have been observed to have
defects in mitochondrial content, structure, and function,
with possible consequences for mitochondrial energetics
[107].
Figure 3presentsaschemaforhowexogenousexposures,
endogenous defences, and mtDNA variants might inﬂuence
ROS production, subsequent DNA damage, and breast
cancer risk.Journal of Oncology 7
9.FunctionalStudiesofMitochondrialChanges
inCancerCells
The functional signiﬁcance of germline variants and somatic
mtDNA alterations with respect to cancer development
is not well understood. However, it is clear that not all
mtDNA alterations or germline variants are functionally
signiﬁcant[85,108–112].Indeed,themajorityofthesomatic
mtDNA alterations identiﬁed so far does not have clear
pathogenicroles,andmaysimplyrepresenttheconsequences
of genomic instability and oxidative DNA damage during
the multistep carcinogenic process [110]. However, a small
numberofalterationsmayallowaselectivegrowthadvantage
for tumorigenesis [113] or may initiate cross-talk with the
nucleus, thereby altering expression of genes involved in
energy metabolism and tumorigenesis [110]. The mtDNA
G10398A polymorphism, which results in the substitution
of threonine for alanine within the NADH dehydrogenase
(ND3) subunit of Complex I and has been associated
with increased risk of breast cancer in African-Americans
in some studies, may lead to increased ROS production
[24]. Although the eﬀect of each individual alteration or
variant may be subtle, cumulatively such changes may have
functional consequences.
10. Recommendations for Further Research
To date, few studies have examined the association of genetic
variants or somatic mutations in mitochondrial DNA with
the risk of breast cancer. In addition, few studies have
investigated risk in association with interactions between
speciﬁcgeneticvariants,orwithinteractionsbetweengenetic
variants and established breast cancer risk factors (e.g.,
alcohol consumption and hormone therapy). Below we
describe several promising directions for exploring the role
of mitochondrial DNA in the development of breast cancer.
11. Genome-WideAssociation Studies
Disease-associated mutations in high-(BRCA1/2)o r
moderate-risk (TP53, PTEN, LKB1, CDH1, ATM, RAD50,
CHEK2) susceptibility genes identiﬁed to date explain
only 25% of the familial aggregation of breast cancers and
only a smaller proportion (∼5%–10%) of sporadic disease
[3, 114, 115]. Thus it is clear that there must be other
candidate genes that contribute modestly to risk [116].
Genome-wide association studies (GWAS) represent one
approach to the identiﬁcation of such genes, and their
conduct has been facilitated by the development of the
HapMap, a genome-wide database of patterns of human
genetic variation [99, 117]. GWAS have the potential
not only to facilitate risk prediction but also to provide
novel insights into disease mechanisms [99]. However, the
HapMap focuses on nuclear DNA, and, to date, there have
been no genome-wide association studies of mtDNA and
breast cancer risk. However, such studies are warranted in
light of the fact that small-scale studies that have tested a
limited number of mtDNA polymorphisms have provided
some support for a role for mtDNA variants in inﬂuencing
breast cancer risk. Given that most associations identiﬁed
through genome-wide studies do not involve previous
candidate genes, the results of genome-wide studies may
immediately suggest new biological hypotheses [99]a n d
provide a basis for functional studies. In view of the
putative role of oxidative stress in carcinogenesis, and of
the mitochondria as a major source of ROS production,
such studies have the potential to provide valuable insights
into the role of the mitochondria in the etiology of breast
cancer.
In order to investigate the pathogenic signiﬁcance of
germline variants and somatic mtDNA alterations, addi-
tional functional studies of the eﬀects of alterations in the
mitochondrial genome of cancer cells are required.
12. Interplaybetween Mitochondrial and
Nuclear DNA Variants
In addition to focusing on the association of polymor-
phisms in mitochondrial DNA with breast cancer risk, the
interplay between mitochondrial DNA variants and nuclear
DNA variants also merits examination. For example, the
subunits of complex II of the respiratory chain complex
are encoded entirely by nuclear genes, and three of these
genes have been shown to be tumor suppressors [118].
Furthermore, mitochondrial DNA synthesis, replication,
transcription, and translation are under nuclear control
[119], and nuclear-mitochondrial communication disorders
have been described, which result in a loss of integrity
of the mitochondrial genome [118]. Therefore, if genome-
wide association studies uncover genetic variants associated
with breast cancer risk, a next step would be to conduct
studies focusing on nuclear DNA (nDNA) variants that
encode for mitochondrial proteins, to examine both the
association between these variants and breast cancer risk
and the interaction between nDNA and mtDNA variants in
relation to risk.
13. Conclusion
To date, most studies examining the role of mitochondrial
damage in carcinogenesis have focused on mtDNA somatic
mutations. In view of the putative role of oxidative stress in
carcinogenesis, and of the mitochondria as a major source of
ROS production, the role of mitochondrial DNA variants in
the etiology of breast cancer represents a potentially promis-
ing area of study. Genome-wide association studies are likely
to identify new mtDNA variants which modify breast cancer
risk. In addition to assessing the main eﬀects of speciﬁc
variants, gene-gene and gene-environment interactions are
likely to explain a greater proportion of the variability
in breast cancer risk. The results of such studies might
have translational potential, given that they may provide
insight into the biological processes underlying breast cancer
development, and, hence, suggest strategies for prevention
and therapy [99].8 Journal of Oncology
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